ATRA Stock Forecast: Atara Biotherapeutics, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Atara Biotherapeutics, Inc. hold a median 12-month price target of $13 — +105.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 74 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Atara Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (81): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (12): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ATRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ATRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +105.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 May 2026 | Freedom Broker | Upgrade | Hold | $4.00 → $10 |
| 8 May 2026 | Canaccord Genuity | Upgrade | Buy | — |
| 21 Jan 2026 | Freedom Broker | Downgrade | Sell | — |
| 13 Jan 2026 | Canaccord Genuity | Downgrade | Hold | — |
| 19 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 11 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 28 Jan 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 17 Jan 2025 | Canaccord Genuity | Maintains | Buy | — |
| 20 Dec 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 13 Nov 2024 | Canaccord Genuity | Maintains | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 16 Aug 2024 | Mizuho | Upgrade | Outperform | — |
| 13 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 17 July 2024 | Goldman Sachs | Maintains | Sell | — |
| 22 May 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 1 Apr 2024 | Stifel | Maintains | Hold | — |
| 10 Nov 2023 | Goldman Sachs | Maintains | Sell | — |
| 9 Nov 2023 | Evercore ISI Group | Downgrade | In-Line | — |
| 9 Nov 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ATRA.
This page is one stock. Monday covers all of them.
ATRA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ATRA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Atara Biotherapeutics, Inc. returned −52.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ATRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 16.5×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 9% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 69.7%
- Operating margin
- —
- Net margin
- —
Higher than 82% of US stocks
- Return on equity
- —
- Return on assets
- −27.2%
- Dividend yield
- —
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Atara Biotherapeutics, Inc. has a market value of $64.6M and an enterprise value of $64.2M.
Revenue in the twelve months to 30 June 2026: $6.2M. The latest quarter shrank 96.4% year on year.
Net income over the same four quarters: −$16.7M, a −269.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$21.9M.
forward P/E: 4.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Atara Biotherapeutics, Inc. employs 10 people — $619K of revenue per employee.
Data provided by Twelve Data
ATRA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ATRA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Atara Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ATRA
What is the ATRA stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Atara Biotherapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ATRA stock a buy right now?
Of the 3 analysts covering Atara Biotherapeutics, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atara Biotherapeutics, Inc. 74 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ATRA?
As at 21 Nov 2026, Atara Biotherapeutics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (81 of 100).
Will ATRA stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +105.4% from the last close, and Ticker Nerd's factor model ranks Atara Biotherapeutics, Inc. 74 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ATRA stock forecast for 2030?
No analyst covering Atara Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $18 over the next 12 months.
How has ATRA stock performed over the past year?
Atara Biotherapeutics, Inc. returned -52.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Atara Biotherapeutics, Inc. do?
Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy. Atara Biotherapeutics develops off-the-shelf cell-based therapies designed to address serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy. Atara Biotherapeutics develops off-the-shelf cell-based therapies designed to address serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. Its current portfolio centers on Epstein-Barr virus (EBV)-targeted T-cell programs and next-generation CAR T candidates, reflecting a platform built to harness donor-derived immune cells for precision treatment approaches. The company’s product development activities include therapies aimed at EBV-driven diseases and B-cell malignancies, positioning it within the broader cell therapy and immuno-oncology markets. Headquartered in Thousand Oaks, California, Atara Biotherapeutics serves the evolving demand for advanced immunotherapies that can be manufactured and deployed without traditional patient-specific cell engineering.
CEO Dr. Anhco Nguyen Ph.D. · 10 employees · United States · https://www.atarabio.com